Gastrointestinal Cancer News

Can-Fite BioPharma Ltd. has submitted an application to the European Medicines Agency for orphan drug designation of CF102 for the treatment of hepatocellular carcinoma, according to a press release from the manufacturer.

PHILADELPHIA — HPV vaccination of women aged 18 to 25 years provides strong combined protection against HPV 16/18 infection at three anatomical sites among those with and without prior HPV exposure, according to study findings presented at the American Association for Cancer Research Annual Meeting.

SillaJen, Inc. has reached an agreement with the FDA on a Special Protocol Assessment for a phase 3 clinical trial of its drug Pexa-Vec for the treatment of advanced liver cancer and will begin enrolling patients later this year, according to a press release.

In a new study, alpha-fetoprotein measurement in combination with ultrasound improved surveillance effectiveness in patients with cirrhosis, according to published data in The American Journal of Gastroenterology.

Two out of three people diagnosed with invasive cancer survive at least 5 years, according to data published in CDC’s Morbidity and Mortality Weekly Report.

Statin use was not linked to a greater survival rate in patients with colorectal cancer, according to study results.

Cologuard, a noninvasive colon cancer screening test, is now covered for more than 90 million Medicare and commercially insured individuals as a result of several insurance providers covering the test, the manufacturer announced today.

Screening colonoscopy has significantly improved prevention and early detection of colorectal cancers in Germany since it was introduced in October 2002, according to a 10-year analysis.

The risk for a variety of cancers in patients with inflammatory bowel disease can be linked to chronic intestinal inflammation or immunosuppressive therapies, according to findings in a recently published review article.

In a phase 2 clinical study, patients with advanced hepatocellular carcinoma displayed improved progression-free survival and time to progression survival rates after treatment with bavituximab and nexavar, according to data presented at the 2015 Society of Surgical Oncology Annual Cancer Symposium.